hiPSC-Cardiomyocytes as Cell Therapy for Heart Failure
-
hiPSC
2 weeks
-
Cardiomyocytes
3 days
-
Cardiomyocytes Aggregate
Long term
Research & Development
Heart failure treatment remains to be an unmet need. Available therapies aim to improve survival, decrease recurrent MI events, and provide symptomatic relief in post-MI patients, falling short of addressing the root cause of heart failure: permanent myocardial damage.
Restoring heart function by remuscularization using iPSC-derived cardiomyocytes is the core of T&R Biofab’s heart cell therapy protocol. Our protocol is:
Effective: Our solid laboratory and pre-clinical studies show that differentiated cardiomyocytes, once injected into the damaged myocardium, improved left ventricular ejection fraction (LVEF) and cardiac volumes weeks after myocardial infarction.
Accessible: We are developing our heart cell therapy technology to create accessible reserves of cryopreserved, purified, and functional heart spheroids ready for patient administration upon thawing, with hopes to bringing off-the-shelf, allogeneic heart cell therapy closer to clinical reality.
Minimally-invasive: Our cardiomyocyte spheroid protocol is being developed especially for commercially available heart catheters. If successful, a catheter-based heart cell therapy would be a game changer – enabling safer treatments with fewer complications and shorter recovery periods compared to open-chest surgery.
Related articles / Patents
ㆍ Effect and application of “cryopreserved cardiac spheroids” for myocardial infarction therapy. Clinical Translational Medicine, 2022